Subjective cognitive decline as an early marker of cognitive impairment in Parkinson's disease.
7 affiliations
- 1Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg. [email protected].
- 2Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg.
- 3Centre Hospitalier de Luxembourg, Strassen, Luxembourg.
- 4Bonn-Aachen International Center for IT, University of Bonn (b-it), Bonn, Germany.
- 5Fraunhofer Institute for Algorithms and Scientific Computing (SCAI), Augustin, Germany.
- 6Institute for Digital Medicine, University Hospital Bonn, Bonn, Germany.
- 7Luxembourg Institute of Health (LIH), Strassen, Luxembourg.
Abstract
Cognitive impairment is one of the non-motor symptoms with the greatest impact on patients and caregiver quality of life. Given its onset and significant relevance during the prodromal phase of Parkinson's disease (PD), and its potential role as an at-risk state for cognitive impairment, this study investigated the role of subjective cognitive decline in PD (PD-SCD) as an early prognostic marker of subsequent cognitive impairment to enhance timely detection and prediction. Additionally, it evaluated how mood-related symptoms (depression, anxiety and apathy) influence this relationship. Data from 577 people with Parkinson's disease (PwPD) and 308 control participants from the Parkinson's Precision Medicine Initiative (PPMI) cohort, together with 142 PwPD from the Luxembourg Parkinson's Study cohort, were analyzed over four visits. PD-SCD, with a baseline prevalence of 21.66% in PPMI and 18.31% in the Luxembourg Parkinson's Study, was associated with an at-risk state for cognitive decline over time. Higher levels of mood-related symptoms (apathy, depression, and anxiety) were observed in the PD-SCD group compared with the people with Parkinson's disease presenting normal cognition group (PD-NC) depending on the cohort. In addition, apathy and depression were cross-sectionally associated with higher levels of subjective cognitive complaints (SCC), underscoring their role as a key feature of the PD-SCD clinical profile, without masking the association between PD-SCD and cognitive impairment. Overall, PD-SCD emerged as a relevant at-risk state of cognitive impairment in PD and as a potential dynamic tracker of cognitive impairment trajectories, highlighting its clinical relevance within the continuum of cognitive impairment in PD.
Related
- Association of Cognitive Reserve and Chronic Disease Comorbidity with the Risk of Progression from Subjective Cognitive Decline to Objective Cognitive Impairment: A Cohort Study Among Chinese Community-Dwelling Older Adults.
- Episodic memory-associated weighted atrophy network mapping in mild cognitive impairment and subjective cognitive decline: a multi-center study
- Prediction of cognitive impairment in Parkinson’s disease using TabPFN: an integrative analysis of clinical data, longitudinal trajectories, and lipidomics
- Enhancing deep sleep with auditory stimulation to boost cognitive training responsiveness in people with Parkinson's disease and mild cognitive impairment: Rationale and design of the double-blind randomized controlled trial PD-CogT-Sleep
- Plasma ceramide ratios define metabolic–inflammatory associations with cognitive impairment in Parkinson’s disease
BibTeX
@article{tirado2026subjective,
title = {{Subjective cognitive decline as an early marker of cognitive impairment in Parkinson's disease.}},
author = {Gabriel Martinez Tirado and Patricia Martins Conde and Stefano Sapienza and Holger Fröhlich and Claire Pauly and Sonja R Jónsdóttir and Rejko Krüger and Jochen Klucken and NCER-PD consortium},
journal = {Journal of neurology},
year = {2026},
month = nov,
doi = {10.1007/s00415-026-14235-9},
url = {https://europepmc.org/article/MED/43007516},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Subjective cognitive decline as an early marker of cognitive impairment in Parkinson's disease.
AU - Gabriel Martinez Tirado
AU - Patricia Martins Conde
AU - Stefano Sapienza
AU - Holger Fröhlich
AU - Claire Pauly
AU - Sonja R Jónsdóttir
AU - Rejko Krüger
AU - Jochen Klucken
AU - NCER-PD consortium
PY - 2026
DA - 2026/11/10
JO - Journal of neurology
DO - 10.1007/s00415-026-14235-9
UR - https://europepmc.org/article/MED/43007516
AB - Cognitive impairment is one of the non-motor symptoms with the greatest impact on patients and caregiver quality of life. Given its onset and significant relevance during the prodromal phase of Parkinson's disease (PD), and its potential role as an at-risk state for cognitive impairment, this study investigated the role of subjective cognitive decline in PD (PD-SCD) as an early prognostic marker of subsequent cognitive impairment to enhance timely detection and prediction. Additionally, it evaluated how mood-related symptoms (depression, anxiety and apathy) influence this relationship. Data from 577 people with Parkinson's disease (PwPD) and 308 control participants from the Parkinson's Precision Medicine Initiative (PPMI) cohort, together with 142 PwPD from the Luxembourg Parkinson's Study cohort, were analyzed over four visits. PD-SCD, with a baseline prevalence of 21.66% in PPMI and 18.31% in the Luxembourg Parkinson's Study, was associated with an at-risk state for cognitive decline over time. Higher levels of mood-related symptoms (apathy, depression, and anxiety) were observed in the PD-SCD group compared with the people with Parkinson's disease presenting normal cognition group (PD-NC) depending on the cohort. In addition, apathy and depression were cross-sectionally associated with higher levels of subjective cognitive complaints (SCC), underscoring their role as a key feature of the PD-SCD clinical profile, without masking the association between PD-SCD and cognitive impairment. Overall, PD-SCD emerged as a relevant at-risk state of cognitive impairment in PD and as a potential dynamic tracker of cognitive impairment trajectories, highlighting its clinical relevance within the continuum of cognitive impairment in PD.
SN - 0340-5354
SN - 1432-1459
ER -